190 related articles for article (PubMed ID: 35025929)
1. Baseline procalcitonin as a predictor of bacterial infection and clinical outcomes in COVID-19: A case-control study.
Atallah NJ; Warren HM; Roberts MB; Elshaboury RH; Bidell MR; Gandhi RG; Adamsick M; Ibrahim MK; Sood R; Bou Zein Eddine S; Cobler-Lichter MJ; Alexander NJ; Timmer KD; Atallah CJ; Viens AL; Panossian VS; Scherer AK; Proctor T; Smartt S; Letourneau AR; Paras ML; Johannes S; Wiemer J; Mansour MK
PLoS One; 2022; 17(1):e0262342. PubMed ID: 35025929
[TBL] [Abstract][Full Text] [Related]
2. Searching for a role of procalcitonin determination in COVID-19: a study on a selected cohort of hospitalized patients.
Dolci A; Robbiano C; Aloisio E; Chibireva M; Serafini L; Falvella FS; Pasqualetti S; Panteghini M
Clin Chem Lab Med; 2020 Nov; 59(2):433-440. PubMed ID: 33554505
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic stewardship: Early discontinuation of antibiotics based on procalcitonin level in COVID-19 pneumonia.
Roy A; Powers HR; Craver EC; Nazareno MD; Yarrarapu SNS; Sanghavi DK
J Clin Pharm Ther; 2022 Feb; 47(2):243-247. PubMed ID: 34766357
[TBL] [Abstract][Full Text] [Related]
4. C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19.
Pink I; Raupach D; Fuge J; Vonberg RP; Hoeper MM; Welte T; Rademacher J
Infection; 2021 Oct; 49(5):935-943. PubMed ID: 34021897
[TBL] [Abstract][Full Text] [Related]
5. Procalcitonin levels in COVID-19 patients.
Hu R; Han C; Pei S; Yin M; Chen X
Int J Antimicrob Agents; 2020 Aug; 56(2):106051. PubMed ID: 32534186
[TBL] [Abstract][Full Text] [Related]
6. High procalcitonin levels associated with increased intensive care unit admission and mortality in patients with a COVID-19 infection in the emergency department.
Tong-Minh K; van der Does Y; Engelen S; de Jong E; Ramakers C; Gommers D; van Gorp E; Endeman H
BMC Infect Dis; 2022 Feb; 22(1):165. PubMed ID: 35189826
[TBL] [Abstract][Full Text] [Related]
7. Is procalcitonin a part of human immunological response to SARS-CoV-2 infection or "just" a marker of bacterial coinfection?
Lugito NPH
Curr Res Transl Med; 2021 May; 69(2):103289. PubMed ID: 33845428
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Procalcitonin's Utility to Predict Concomitant Bacterial Pneumonia in Critically Ill COVID-19 Patients.
Patel N; Adams C; Brunetti L; Bargoud C; Teichman AL; Choron RL
J Intensive Care Med; 2022 Nov; 37(11):1486-1492. PubMed ID: 35711161
[No Abstract] [Full Text] [Related]
9. Prognostic value of procalcitonin in cancer patients with coronavirus disease 2019.
Tiutan T; Wallins JS; Brown S; Gonen M; Korenstein D
Clin Chem Lab Med; 2023 Jan; 61(2):339-348. PubMed ID: 36367353
[TBL] [Abstract][Full Text] [Related]
10. Effects of procalcitonin on antimicrobial treatment decisions in patients with coronavirus disease 2019 (COVID-19).
Conlon ASC; Chopra Z; Cahalan S; Cinti S; Rao K
Infect Control Hosp Epidemiol; 2023 Aug; 44(8):1314-1320. PubMed ID: 36330692
[TBL] [Abstract][Full Text] [Related]
11. Procalcitonin and secondary bacterial infections in COVID-19: association with disease severity and outcomes.
Vazzana N; Dipaola F; Ognibene S
Acta Clin Belg; 2022 Apr; 77(2):268-272. PubMed ID: 32966166
[TBL] [Abstract][Full Text] [Related]
12. Respiratory multiplex PCR and procalcitonin to reduce antibiotic exposure in severe SARS-CoV-2 pneumonia: a multicentre randomized controlled trial.
Fartoukh M; Nseir S; Mégarbane B; Cohen Y; Lafarge A; Contou D; Thille AW; Galerneau LM; Reizine F; Cour M; Klouche K; Navellou JC; Bitker L; Rousseau A; Tuffet S; Simon T; Voiriot G;
Clin Microbiol Infect; 2023 Jun; 29(6):734-743. PubMed ID: 36681325
[TBL] [Abstract][Full Text] [Related]
13. Differences between COVID-19 and suspected then confirmed SARS-CoV-2-negative pneumonia: A retrospective study from a single center.
Chen X; Yang Y; Huang M; Liu L; Zhang X; Xu J; Geng S; Han B; Xiao J; Wan Y
J Med Virol; 2020 Sep; 92(9):1572-1579. PubMed ID: 32237148
[TBL] [Abstract][Full Text] [Related]
14. Procalcitonin as a predictor of severity and mortality in a cohort of patients hospitalised with COVID-19.
Ahmed S; Ahmed ZA; Rashid NH; Mansoor M; Siddiqui I; Jafri L
Malays J Pathol; 2021 Dec; 43(3):375-380. PubMed ID: 34958058
[TBL] [Abstract][Full Text] [Related]
15. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting.
Hughes S; Troise O; Donaldson H; Mughal N; Moore LSP
Clin Microbiol Infect; 2020 Oct; 26(10):1395-1399. PubMed ID: 32603803
[TBL] [Abstract][Full Text] [Related]
16. Procalcitonin for individualizing antibiotic treatment: an update with a focus on COVID-19.
Wolfisberg S; Gregoriano C; Schuetz P
Crit Rev Clin Lab Sci; 2022 Jan; 59(1):54-65. PubMed ID: 34517744
[TBL] [Abstract][Full Text] [Related]
17. Bacterial and Fungal Coinfection in Critically Ill COVID-19 Cases and Predictive Role of Procalcitonin During the First Wave at an Academic Health Center.
Alnimr AM; Alshahrani MS; Alwarthan S; AlQahtani SY; Hassan AA; BuMurah NN; Alhajiri S; Bukharie H
J Epidemiol Glob Health; 2022 Jun; 12(2):188-195. PubMed ID: 35397070
[TBL] [Abstract][Full Text] [Related]
18. Procalcitonin Identifies Cell Injury, Not Bacterial Infection, in Acute Liver Failure.
Rule JA; Hynan LS; Attar N; Sanders C; Korzun WJ; Lee WM;
PLoS One; 2015; 10(9):e0138566. PubMed ID: 26393924
[TBL] [Abstract][Full Text] [Related]
19. Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients in a MERS-CoV Endemic Area.
Barry M; AlMohaya A; AlHijji A; Akkielah L; AlRajhi A; Almajid F; Alsharidi A; Al-Shahrani FS; Alotaibi NH; Alanazi A; Ghonem L; Alhetheel A; Alsubaie S; Memish ZA
J Epidemiol Glob Health; 2020 Sep; 10(3):214-221. PubMed ID: 32954712
[TBL] [Abstract][Full Text] [Related]
20. A risk score based on procalcitonin for predicting acute kidney injury in COVID-19 patients.
Wang RR; He M; Kang Y
J Clin Lab Anal; 2021 Jun; 35(6):e23805. PubMed ID: 34032326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
